BUSINESS BRIEFING / COURTS
Times Wire Reports
Amgen Inc. won an appeals court ruling that helps preserve its $5.6-billion-a-year franchise in anemia medicines from competition from Roche Holding’s Mircera drug.
An appeals court upheld part of a patent-infringement verdict won by Amgen, while ordering a new trial on other aspects. Roche can challenge the scope of an order that prevents U.S. sales of Mircera until at least 2012, the court ruled.
